Rampur Indian Single Malt, the globally acclaimed whisky from Radico Khaitan Limited (NSE: RADICO), has unveiled a new brand positioning, ’43° | 2° – Born in Nature’s Frequency’. This innovative positioning emphasizes the natural maturation process influenced by the seasonal temperature extremes of Rampur’s Himalayan foothills. The brand’s new platform highlights the cask’s expansion and contraction due to the 43°C summers and 2°C winters, which shapes the whisky’s character.

Unique Climate Influence

The natural positioning is built on the unique climatic conditions of Rampur’s home. The seasonal temperature swings are integral to the maturation process, which is now the signature of the brand. This climate influence is also the subject of international scientific research. Rampur Distillery has been selected to represent Asia in The 8 Continent Series, an international study examining how geographical and climatic conditions affect single malt whisky maturation.

Cultural and Symbolic Significance

The new platform, ’43° | 2° – Born in Nature’s Frequency’, connects the rhythm of the natural world with the maturation process. The number 432, formed by combining 43 and 2, carries cultural and symbolic associations with harmony, balance, and the rhythm of nature. This provides a creative lens to tell a more expansive story about Rampur’s origins and craft.

Market Expansion and Recognition

The campaign is being rolled out across on-trade and retail touchpoints to create a consistent expression of the brand’s new platform. It is complemented by digital storytelling featuring actor Mihir Ahuja, which brings the idea of 43° | 2° to a wider audience. This announcement comes as Radico Khaitan continues to strengthen its premium and luxury portfolio, with its Prestige & Above segment recording 35.8% volume growth in Q1 FY2027.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Radico Khaitan Limited

Radico Khaitan Limited belongs to the Consumer Defensive › Beverages – Wineries & Distilleries sector. Here’s a quick read on where the business and the stock stand today.

Radico posts a 8.5% three-month gain, but softens in the last few weeks. Revenue grows at 24.6% and profits at 40.0% CAGR. Both numbers are exceptional. The PEG of 2.11 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The stock gives back 2.2% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 24.6% and profits at 40.0%, with D/E of 0.40. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.11 premium is usually justified. Check Fundamentals of Radico Khaitan Limited.

Mukka Proteins Limited (NSE: MUKKA) announced its financial results for the second quarter and half year ended September 30, 2026, showcasing a robust performance. The company reported a 108.06% year-on-year growth in revenue, reaching ₹ 5,088.70 Mn, and a significant 157.51% year-on-year increase in PAT, standing at ₹ 177.27 Mn. These impressive figures highlight Mukka Proteins’ strong execution and growth trajectory.

Consolidated Financial Performance

The consolidated revenue for Q2 FY27 was ₹ 5,088.70 Mn, compared to ₹ 4,896.54 Mn in Q1 FY27 and ₹ 2,445.81 Mn in Q2 FY26. The PAT for the quarter stood at ₹ 177.27 Mn, up from ₹ 68.84 Mn in Q2 FY26. The EBITDA increased to ₹ 501.18 Mn, marking a 90.73% year-on-year increase. The EBITDA margin stood at 9.85%, down slightly from 10.74% in the same quarter last year.

Standalone Financial Performance

On a standalone basis, revenue for Q2 FY27 was ₹ 4,115.42 Mn, reflecting an 85.15% year-on-year growth. The PAT rose to ₹ 106.99 Mn from ₹ 36.10 Mn in Q2 FY26. The EBITDA increased to ₹ 357.53 Mn, up 84.41% year-on-year. The PAT margin expanded to 2.60%, up from 1.62% in the same quarter last year.

The growth was supported by strong export demand, improved realizations, and favorable industry dynamics amid global fishmeal supply constraints. However, geopolitical disruptions and supply-chain constraints resulted in the execution of certain shipments being deferred to October 2026.

Mukka Proteins’ capacity expansion, including the commencement of commercial production at the Oman facility, has increased the Group’s overall production capacity and strengthened its manufacturing presence in the Middle East. The U.S. FDA facility registration and USDA NOP Inputs Attestation for Eco Sphere Organic Fertilizer are expected to support product acceptance in organic-farming markets, including the United States.

Looking ahead, Mukka Proteins aims to ramp up operations at the Al Juba facility, execute deferred shipments, deepen market access, and improve operating efficiencies across the Group.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Mukka Proteins Limited

Mukka Proteins Limited belongs to the Consumer Defensive › Packaged Foods sector. Here’s a quick read on where the business and the stock stand today.

Mukka posts a 22.0% three-month gain, but softens in the last few weeks. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. The PEG of 2.12 makes it expensive versus peers. The premium needs earnings to catch up quickly. The stock gives back 5.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 22.0% in three months on 6.7% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Mukka Proteins Limited.

Jaro Institute of Technology Management and Research Limited (JARO) showcased a robust financial performance in H1 FY27, with a 21% year-on-year (YoY) increase in Profit After Tax (PAT) and a 15% rise in total income. The company’s sustained revenue growth, improved profitability, and strategic expansion of academic partnerships and future-ready program portfolios underpinned this performance.

Strong Earnings Growth

In Q2 FY27, JARO’s PAT rose 9% YoY to Rs. 1,854 lakh, reflecting stronger earnings growth. The company’s PAT margin remained healthy at approximately 21% of revenue from operations. This robust performance continued in H1 FY27, with PAT growing 21% to Rs. 2,971 lakh, outperforming revenue growth.

Operational Traction and Strategic Expansion

JARO witnessed encouraging operational traction, with learner volumes registering 7% YoY growth and gross bookings growing 13% to Rs. 22,710 lakh during Q2 FY27. The company expanded its academic ecosystem through new partnerships with prestigious institutions, including IIT Kharagpur and CHRIST (Deemed to be University), Bengaluru. These strategic partnerships aim to develop a diversified, industry-relevant learning portfolio.

Future-Ready Initiatives

JARO introduced its #GrowWithJaro initiative in association with IIT Madras Pravartak to democratise AI literacy and enable mass upskilling across India. This initiative aims to bridge the gap between AI adoption and practical AI capabilities by making AI-focused education more accessible and affordable. As JARO enters the second half of FY27, it remains focused on strengthening learner engagement and scaling its future-ready program portfolio.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Jaro Institute of Technology Management and Research Limited

Jaro Institute of Technology Management and Research Limited belongs to the Consumer Defensive › Education & Training Services sector. Here’s a quick read on where the business and the stock stand today.

Jaro drops 17.1% over three months and trades near its 52-week lows. The PEG of 0.24 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Revenue grows at 30.9% and profits at 65.6% CAGR. Both numbers are exceptional. The stock sits at 7% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 30.9% and profits at 65.6% CAGR, with D/E of 0.37. Meanwhile, the stock dips 17.1% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Jaro Institute of Technology Management and Research Limited.